China Biologic Products Reports Two SFDA Successes

Published: May 01, 2008

May 1, 2008 -- China Biologic Products, Inc. (OTCBB: CBPO) received SFDA approval to start the production of Cryoprecipitate, a frozen blood product prepared from plasma, and also to begin a clinical trial of Human Prothrombin Complex, a new offering. China Biologic bases its business on plasma-derived biopharmaceuticals. Its human albumin products are used to increase blood volume and its immunoglobulin products treat and prevent diseases. More details...

Back to news